Babylon SPAC Presentation Deck

Condensed Consolidated Statement of Cash Flows For the Years Ended December 31, $ in thousands Cash Flow from Operating Activities Adjusted EBITDA 1 Share of Net Loss of Associates 2 Net Working Capital Adjustments Net Cash Used in Operating Activities Cash Flow from Investing Activities 3 Development Costs Capitalized 4 Payment for Acquired Trade Assets 5 Purchase of Shares in Associates Purchase of PPE Interest Received Net Cash Used in Investing Activities 6 Cash Flow from Financing Activities Proceeds from Issuance of Convertible Loan Notes Repayment of Loans Net Proceeds from Issuance of Share Capital Other Net Cash Provided by Financing Activities Cash and Cash Equivalents at January 1, Net (Decrease) / Increase in Cash and Cash Equivalents Effect of Movements in Exchange Rate on Cash Held Cash and Cash Equivalents at December 31, Source: Management reporting. 2019A 2020A (152,358) 8,744 (143,614) (36,036) (1,915) 1,015 (36,936) 51,064 (16,025) 319,561 (2,079) 352,251 46,031 171,971 (3,114) 214,888 (146,155) 1,124 1,601 (143,430) (36,509) (25,671) (10,000) (719) 673 (72,226) 100,000 1,851 (1,793) 100,058 214,888 (115,598) 2,467 101,757 Commentary 1 Relates to Babylon's investment in Higi 2 Greater portion of revenue was recognized from advanced payments from Licensing 3 Consistent with 2019, slight increase as a result of higher amortization and the mid-year restructure 4 Investments in a controlling stake in First Choice Medical Group 5 Investment in Higi 6 Issuance of $100M worth of convertible loan notes in 2020, which were converted into equity in two tranches, with $30M converting in December 2020 and $70M converting in June 2021 95

View entire presentation